



GenoTrim™ Clinical Data Supports Significance of Genes and Weight Troubles

GenoTrim genes are statistically significant among overweight persons. Genes can help to DNA-customize a nutritional solution for weight management, says data presented at SupplySide West International Conference.

San Diego, CA (PRWEB) October 24, 2006 -- Salugen, Inc., (www.salugen.com) a leading personalized healthcare company, announced today that clinical data related to its DNA-customized nutritional solution for weight, GenoTrim™ (www.genotrim.com), was accepted for poster display at this past week's Supply Side West International Trade Show and Conference at the Venetian in Las Vegas, Nevada.

Clinical data from the Dutch Investigation to Evaluate Treatments for DNA-Customized Nutritional Solutions (D.I.E.T. study) has affirmed earlier data that the genes measured to provide DNA-customized GenoTrim (www.genotrim.com) are statistically significant among overweight persons. In fact, 7 out of 10 subjects had 2 or more GenoTrim genes contributing to their weight problems.

In this observational study, a total of 1,058 subjects from The Netherlands were genotyped in the nutrigenomics laboratory of Salugen, Inc. (San Diego, CA). Each subject was genotyped based upon the following genetic mutations: Sweet Tooth Gene™ [Dopamine D2 Receptor Gene Taq 1 Allele (DRD2 A1), Nervous Eating Gene™ [5-Hydroxytryptamine 2A -1438G/A promoter polymorphism (5-HT2a -1438G/A), New Cell Gene™ [Methylene Tetrahydrofolate Reductase C677T polymorphism (MTHFR C677T), Obesity Risk Gene™ [Leptin Genetic Polymorphism - OB1875 < 208-bp alleles (Leptin OB1875), and the Fat Regulator Gene™ [Peroxisome Proliferator-Activated Receptor-Gamma Gene Pro12Ala polymorphism (PPAR-gamma Pro12Ala Allele).

The Sweet Tooth Gene, associated with sugar and carbohydrate cravings, was present in 38.09% of the study subjects (n=1,058) versus 29% of the literature controls (n=3,259). This difference was significant (Z = 8.393, p = 0.0001). The New Cell Gene, associated with heart health and obesity, was present in 69.85% of the study subjects (n=1,058) versus 54% of the literature controls (n=100). This difference was significant (Z* = 2.23, p = 0.01). The Obesity Risk Gene, associated with obesity rates and hormones, was present in 75.61% of the study subjects (n=1,058) versus 45.6% of the literature controls (n=206). This difference was significant (Z = 5.612, p = 0.0001). The Fat Regulator Gene, associated with fat cell production and weight in utero into adulthood, was present in 25.05% of the study subjects (n=1,058) versus 14% of the literature controls (n=2,245). This difference was significant (Z=17.398, p = 0.001).

The prevalence of genetic combinations is also of interest as 37.81% had 3 or more genes, 73.91% had 2 or more genes. The most common genotypes were Nervous Eating and New Cell Genes (13.42%), New Cell Gene (11.81%), Sweet Tooth, Nervous Eating and New Cell Genes (10.4%) and Nervous Eating Gene (7.84%).

"The findings of the D.I.E.T. Study are consistent with earlier data supporting the initial design of GenoTrim as a DNA-customized weight loss supplement. With 30 years of experience studying the genetics of conditions once thought to be purely driven by behavior, our research continues to show that there is a genetic influence on weight. This data confirms that GenoTrim evaluates important genes and then uses that information to provide an unprecedented, customized nutritional supplement to support weight loss," states Dr. Kenneth Blum, Chief Scientific Officer.

About GenoTrim™

GenoTrim (www.genotrim.com) is a DNA-customized nutritional solution for weight management. Based upon an analysis of five important genes effecting weight, GenoTrim ingredients and dosages are genetically-guided to address the underlying genetic factors involved in hormones and metabolism that Harvard Medical Experts suggest influence 70% to 80% of overweight cases. By addressing genetic factors that make individuals prone to weight problems, GenoTrim supports healthy sleep, digestion, mood, and fat metabolism which results in sustainable weight loss and overall trimming. GenoTrim was unexpectedly test launched in The Netherlands in early 2006 and will be available in the United States in the second half of 2006. For more information on GenoTrim, please visit www.genotrim.com.

About Salugen

Salugen, Inc., a leading personalized healthcare company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit <http://www.salugen.com>.

###

Contact Information

Florina Crews
SALUGEN, INC.
<http://www.salugen.com>
858-535-4825

Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb®. We will be unable to assist you with your inquiry. PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears [here](#).

© Copyright 1997-2006, PRWeb®. PRWeb is a registered trademark of PRWeb International, Inc.

[Terms of Service](#) | [Privacy Policy](#)